Paraneoplastic syndromes are a group of disorders associated with tumors that are prevalent in patients with lymphatic, lung, ovarian or breast cancers.
Fibrocor Therapeutics Inc. has entered into a research and development collaboration with the Mcquade Center for Strategic Research and Development LLC (MSRD).
Scientists at Mount Sinai School of Medicine and U.S. Department of Veterans Affairs have synthesized mothers against decapentaplegic homolog 3 (SMAD3) inhibitors reported to be useful for the treatment of renal, hepatic and pulmonary fibrosis.
Diabetic retinopathy and diabetic kidney disease are frequent microvascular complications of diabetes, both related to exacerbated vascular permeability coming from microvascular barrier malfunctioning.
Guard Therapeutics AB has presented progress within the company’s preclinical development platform, the GTX platform, aimed at developing new peptides based on the endogenous protein α-1-microglobulin.
Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease.
Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
Arrowhead Pharmaceuticals Inc. has filed an application in New Zealand seeking clearance to initiate a phase I/IIa trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement-mediated renal disease, such as immunoglobulin A nephropathy (IgAN).
Researchers from Taisho Pharmaceutical Co. Ltd. have reported initial evaluation of novel pyrazolylpyridine derivatives with increased selectivity for inhibition of the 20-hydroxyeicosatetraenoic acid (20-HETE) synthase CYP4A11/4F2, to be developed as candidates for the treatment of renal fibrosis.
RSS
